The United States Patent and Trademark Office (USPTO) has issued patent US12583931B2, granting exclusive rights to Nanjing IASO Biotechnology Co., Ltd. for an antibody and a chimeric antigen receptor (CAR) designed to bind specifically to the CD70 protein. The patent details the composition of the CAR, including its binding domain, transmembrane domain, costimulatory domain, and intracellular signaling domain, as well as its application in treating diseases associated with CD70 expression.

This patent grant signifies a new intellectual property right for the assignee, potentially impacting future research, development, and commercialization efforts in the field of CD70-targeted therapies. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, companies operating in the oncology or immunology space, particularly those developing CAR T-cell therapies or antibody-based treatments targeting CD70, should be aware of this granted patent to avoid potential infringement issues.